Century Therapeutics Inc. announced it received a deficiency letter from Nasdaq on February 26, 2025, indicating non-compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Select Market. Despite efforts, the company failed to meet this requirement by the initial compliance deadline of August 26, 2025. Subsequently, Nasdaq approved Century Therapeutics' transfer to The Nasdaq Capital Market on August 27, 2025, and granted an additional 180-day period until February 23, 2026, to regain compliance. The company is considering options, including a reverse stock split, to address the deficiency, though there is no assurance of compliance with this or other Nasdaq listing criteria.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Century Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-085658), on August 29, 2025, and is solely responsible for the information contained therein.